Chugai Pharmaceutical Co Ltd (CHGCF)
42.25
-2.55
(-5.69%)
USD |
OTCM |
Jan 17, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 69.52B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 15.72% |
| Valuation | |
| PE Ratio | 27.02 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 9.191 |
| Price to Book Value | 5.512 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2599 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.29% |
Profile
| Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several notable therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19. |
| URL | http://www.chugai-pharm.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 30, 2025 |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 27, 2024 |
Ratings
Profile
| Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several notable therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19. |
| URL | http://www.chugai-pharm.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 30, 2025 |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 27, 2024 |